A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
Infected Corneal Ulcers
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers|
- Days to cure, with corneal epithelial defect closed, and no inflammatory signs other than minimal injection.
- Safety of study medication use compared to control medications. No untoward reactions or loss of visual acuity (VA) compared with pre-treatment VA findings.
|Study Start Date:||November 2002|
|Study Completion Date:||January 2006|
|Primary Completion Date:||January 2006 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00386958
|United States, California|
|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center|
|Torrance, California, United States, 90502|
|Principal Investigator:||Sherwin J. Isenberg, M.D.||Jules Stein Eye Institute and Harbor-UCLA Medical Center|